India Issues Urgent GLP-1 Drug Safety Alert The Indian Pharmacopoeia Commission (IPC) has issued a public notice on 14 May calling on doctors, patients, and consumers to closely monitor and report any adverse reactions linked to semaglutide and other GLP-1 receptor agonists including dulaglutide, liraglutide, and tirzepatide
Compared to healthy controls, a significant increase in demyelinated area was observed during the acute phase of the disease and even aggravated during relapse (Fig
Join Us Live for a Discussion on Medicare, Democracy, and the Future of Health Care Starting in July 2026, some people with Medicare will be eligible for Medicare coverage of certain weight-loss medications through the new Medicare GLP1 Bridge Program
Repair Matrix Start The Repair Matrix Start is a focused three-part recovery research stack pairing the systemic repair peptides BPC-157 and TB-500 with the copper peptide GHK-Cu
The method provides quicker onset and sustained release of the peptide in research subjects
Customizable Nutrition